Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 4/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155256 | 0.84 | TOP2A (0.42) | TOP2AHSP90AB1IRAK4MAPK14AURKA | |
| SCHEMBL6154506 | 0.84 | ROCK2 (0.47) | TOP2AHSP90AB1IRAK4MAPK14AURKA | |
| SCHEMBL6154711 | 0.84 | TOP2A (0.47) | TOP2AHSP90AB1IRAK4MAPK14AURKA | |
| SCHEMBL6154879 | 0.84 | BRD4 (0.47) | TOP2AHSP90AB1IRAK4MEN1CYP2D6 | |
| SCHEMBL6153952 | 0.82 | DDR1 (0.53) | TOP2AHSP90AB1 | |
| SCHEMBL6153347 | 0.81 | PTK2 (0.41) | TOP2AHSP90AB1IRAK4MAPK14 | |
| SCHEMBL6154636 | 0.80 | TOP2A (0.46) | TOP2AHSP90AB1 | |
| SCHEMBL4144350 | 0.77 | IRAK4 (0.45) | IRAK4AURKARPS6KB1BRD4ATAD2 | |
| SCHEMBL6156929 | 0.77 | MAPK14 (0.47) | TOP2AHSP90AB1MAPK14RPS6KB1 | |
| Hydrochloric Acid SCHEMBL6153321 | 0.76 | IRAK4 (0.44) | IRAK4MEN1CYP2D6KMT2AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | TOP2A 4307/4885HSP90AB1 1463/4885IRAK4 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.